Biljana Naumovic: How JNJ Oncology is driving the future of cancer care
Biljana Naumovic, President US Oncology Solid Tumor at Johnson & Johnson Innovative Medicine, shared on LinkedIn:
“Medicine is evolving – from a one-size-fits-all approach to precision care that’s smarter, faster, and more effective. At Johnson & Johnson Innovative Medicine, we’re not just innovating treatments; we’re revolutionizing how we diagnose and respond to cancer.
Liquid biopsy is a prime example. This breakthrough tool could transform cancer care by catching the disease earlier, bringing results faster and guiding treatment with unmatched precision. That’s why I joined leaders at the International Society of Liquid Biopsy (ISLB) 6th Annual Congress to tackle the opportunities and challenges ahead.
The message was clear: precision medicine isn’t just about technology—it’s about access, equity, and delivering real hope to patients.
Cancer doesn’t wait, and neither should we. Together, we’re pushing the boundaries of what’s possible to transform outcomes and lives.
Explore how JNJ Oncology is driving the future of cancer care.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023